Quiero saber acerca de...

9511

Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices comment on the proposed collection of information. No comments were received and we have therefore made no
adjustments to our estimate, which is as follows:

TABLE 1ESTIMATED ANNUAL REPORTING BURDEN
Number of responses per respondent
Number of respondents
21 CFR section
Average burden per response in hours
Total annual responses
Total hours
Subpart B
314.50alContent and format of a 505b1 or 505b2 application
314.50i1patent certifications:
Form FDA 3542
Form FDA 3542a
314.50i6 amended patent certifications
314.52a, b, and eNDAsnotice of noninfringement of patent certification
314.52cNoninfringement of patent certification notice content
314.53f1Correction of patent information errors by persons other than the NDA holder
314.53f2Correction of patent information errors by the NDA holder
314.60Amendments to unapproved NDA, supplement or resubmission
314.60fpatent certifications for unapproved applications
314.65Withdrawal of unapproved applications
314.70 and 314.71Supplements and other changes to approved application
314.72Changes of ownership of NDAs
314.81Other postmarketing reports 314.81b1 3331
and 3331a field alert reports and followups
314.81b22252Annual reports
314.81b22253Promotional labeling

121

1.15

139

1,921

267,019

281
310
17

2.875
2.084
1

808
646
17

10
15
2

8,080
9,690
34

15

3

45

15

675

22

3

66

0.33 20
minutes
22

24

1

24

10

240

28

1.4

39

1

39

256

8.23

2,106

80

168,480

6
14

1
1.21

6
17

2
2

12
34

492
67

6.57
1.45

3,232
97

150
2

484,800
194

484
626
331

20.3
4.9
141.3

9,834
3,066
46,782

8
40
2

78,672
122,640
93,564

Subpart C
314.94aanddANDA content
314.94a12viii amended patent certifications before approval of ANDA
314.95cNon-infringement of patents ANDAs

229

4.3

987

480

473,760

153
400

1
3

153
1,200

306
400

314.96a1Amendments to unapproved ANDAs
314.96c amendment for pharmaceutical equivalent to a listed drug other than RLD
314.96dpatent certification requirements
314.97Supplements and other changes to ANDAs
314.97b Supplements to ANDA for pharmaceutical equivalent to a listed drug other than RLD
314.99aANDA Applicants: Withdrawal of unapproved ANDAs
314.99aANDA Transfer of ownership

451

36.2

16,311

2
0.33 20
minutes 80

1,304,880

1
100
361

1
1 22.8

1
100
8,237

300
2 80

300
200
658,960

1

1

1

300

300

77
135

2.3
1.24

177
167

2
2

354
334

khammond on DSKJM1Z7X2PROD with NOTICES

Subpart D
314.101aNDA or ANDA filing over protest

1

1

1

0.5 30
minutes
0.5

314.107enotification of court actions or written consent to approval

247

2

494

0.5 30
minutes
247

Subparts G, H, and I
314.420drug master files FDA 3938original amendments
DMFstechnical, administrative, REMS
DMFsannual reports
314.550Promotional material and subpart H applications
36
2,946
2,946
55

27.2
11.4
3.33
11.6

981
33,590
9,834
640

61
8 4
120

59,841
268,720
39,336
76,800

Total

4,118,933.5

VerDate Sep<11>2014

17:04 Feb 12, 2021

Jkt 253001

PO 00000

Frm 00035

Fmt 4703

Sfmt 4703

E:FRFM16FEN1.SGM

16FEN1